Citation
Nagler, Arnon, et al. "Allogeneic Hematopoietic Stem-cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-body Irradiation Plus Cy as Conditioning Regimen--a Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 31, no. 28, 2013, pp. 3549-56.
Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31(28):3549-56.
Nagler, A., Rocha, V., Labopin, M., Unal, A., Ben Othman, T., Campos, A., Volin, L., Poire, X., Aljurf, M., Masszi, T., Socie, G., Sengelov, H., Michallet, M., Passweg, J., Veelken, H., Yakoub-Agha, I., Shimoni, A., & Mohty, M. (2013). Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(28), 3549-56. https://doi.org/10.1200/JCO.2013.48.8114
Nagler A, et al. Allogeneic Hematopoietic Stem-cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-body Irradiation Plus Cy as Conditioning Regimen--a Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2013 Oct 1;31(28):3549-56. PubMed PMID: 23980086.
TY - JOUR
T1 - Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
AU - Nagler,Arnon,
AU - Rocha,Vanderson,
AU - Labopin,Myriam,
AU - Unal,Ali,
AU - Ben Othman,Tarek,
AU - Campos,Antonio,
AU - Volin,Liisa,
AU - Poire,Xavier,
AU - Aljurf,Mahmoud,
AU - Masszi,Tamás,
AU - Socie,Gerard,
AU - Sengelov,Henrik,
AU - Michallet,Mauricette,
AU - Passweg,Jakob,
AU - Veelken,Hendrik,
AU - Yakoub-Agha,Ibrahim,
AU - Shimoni,Avichai,
AU - Mohty,Mohamad,
Y1 - 2013/08/26/
PY - 2013/8/28/entrez
PY - 2013/8/28/pubmed
PY - 2013/12/16/medline
SP - 3549
EP - 56
JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
JO - J Clin Oncol
VL - 31
IS - 28
N2 - PURPOSE: Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than the oral formulation. Comparative studies of outcomes have been performed between oral Bu/Cy and Cy/TBI, but there have been no comparative trials in the era of IV Bu. PATIENTS AND METHODS: We performed a retrospective registry-based study comparing outcomes of patients with AML in first or second remission after alloSCT from sibling donors who underwent IV Bu/Cy (n = 795) or Cy/TBI (n = 864) conditioning. RESULTS: Engraftment rate was 98% and 99% after IV Bu/Cy and Cy/TBI, respectively. Grade 2 to 4 acute graft-versus-host disease (GVHD) was significantly lower in the IV Bu/Cy compared with Cy/TBI group (P < .001). Similarly, chronic GVHD was significantly lower in the IV Bu/Cy compared with Cy/TBI group (P = .003). Cumulative incidence of 2-year nonrelapse mortality (NRM; ± standard deviation [SD]) was 12% ± 1% in the IV Bu/Cy group and 15% ± 2% in the Cy/TBI group (P = .14), and 2-year relapse incidence (RI; ± SD) was 26% ± 3% and 21% ± 1%, respectively (P = .012). Leukemia-free survival (LFS) rate (± SD) was 61% ± 2% after IV Bu/Cy and 64% ± 2% after Cy/TBI (P = .27). In multivariable analysis, adjusting for differences between both groups, patients who received IV Bu/Cy had lower acute and chronic GVHD, higher RI, and a trend toward lower NRM. LFS was not statistically different between the two conditioning regimens. CONCLUSION: This retrospective study shows that final outcomes after myeloablative conditioning using IV Bu/Cy were not statistically different from those after Cy/TBI.
SN - 1527-7755
UR - https://www.unboundmedicine.com/medline/citation/23980086/Allogeneic_hematopoietic_stem_cell_transplantation_for_acute_myeloid_leukemia_in_remission:_comparison_of_intravenous_busulfan_plus_cyclophosphamide__Cy__versus_total_body_irradiation_plus_Cy_as_conditioning_regimen__a_report_from_the_acute_leukemia_working_party_of_the_European_group_for_blood_and_marrow_transplantation_
L2 - https://ascopubs.org/doi/10.1200/JCO.2013.48.8114?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed
DB - PRIME
DP - Unbound Medicine
ER -
